Cushman buys HealthInfo Direct

Share this article:
Cushman Amberg Communications, an independent Chicago-based PR agency, acquired HealthInfo Direct, the Chicago healthcare direct marketing and PR firm. Terms of the deal were not disclosed.

HealthInfo Direct partners Marita Gomez and Matthew Stone become VPs at the combined company, which will continue to operate as Cushman Amberg, with Gomez in charge of healthcare PR and Stone heading up healthcare direct marketing. Both report to president and CEO Tom Amberg.

“They bring substantial knowledge and capability in healthcare and direct marketing that adds tremendously to our strengths,” said Amberg.

“They're highly regarded in the healthcare industry,” he said. “There's great synergy between what they do for their clients and what we do for our clients.”

With offices in Chicago and St. Louis, Cushman Amberg has around 35 clients, including GE Healthcare Financial Services, US Cellular, the US Futures Exchange and Intercall. HealthInfo Direct brings nine clients, including several pharma firms, to the company's roster.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...